NSE · BLISSGVS · Pharmaceuticals
Bliss GVS Pharma Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹212 Cr with net profit ₹32 Cr — a 15.33% net margin, versus 12.9% the period before.
Shareholding
As of 2026-06-30
- Promoter35.01%
- Public47.45%
- FII8.07%
- DII9.47%
46,767 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 4.69× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 4. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #10 of 50 by market cap · medians across 42 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,562 Cr | 423.85 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,434 Cr | 159.09 | 9.4 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,961 Cr | 114.27 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,264 Cr | 326.41 | 19.62 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,863 Cr | 116.76 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,767 Cr | 69.25 | 5.06 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,825 Cr | 109.73 | 4.56 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,757 Cr | 79.34 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,071 Cr | 165.62 | 6.51 | 12.36% | 18.59% |
| Bliss GVS Pharma Ltd.(this company) | ₹4,836 Cr | 141.61 | 4.04 | 8.95% | 11.15% |
AI analysis
AI-generated · google/gemini-2.5-flashBliss GVS Pharma Ltd. has a market capitalization of Rs 5119 Cr. The company reported a revenue of Rs 773.53 Cr with a profit margin of 13.93%. Its PE ratio is 149.91 and EPS is 12.44. The 52-week high for the share price was Rs 553, and the 52-week low was Rs 118.
Positives
- +The debt-to-equity ratio of 0.05 is low, suggesting limited financial leverage.
- +The Return on Capital Employed (ROCE) is 16.483%, which indicates efficient use of capital.
- +The dividend yield is 20%, which may be attractive to dividend-seeking investors.
Negatives
- −The company is under LT-ASM Stage 4 surveillance, indicating increased regulatory scrutiny.
- −The promoter shareholding decreased from figures that might have been higher in previous periods, though historical data is incomplete for direct comparison.
- −Revenue growth of 5.1% could be considered moderate.
- −The PE ratio of 149.91 is higher than the EPS of 12.44, suggesting a high valuation.
Financial Performance
Bliss GVS Pharma Ltd. generated a revenue of Rs 773.53 Cr, demonstrating a revenue growth of 5.1%. The company's profit margin stood at 13.93%. Over the past year (Mar 2025 to Mar 2026), annual revenue fluctuated, with a high of Rs 211.54 Cr in Mar 2026 and a low of Rs 156 Cr in Mar 2025. Net profit also varied, reaching a high of Rs 32.42 Cr in Mar 2026 and a low of Rs 11.45 Cr in Mar 2025.
Profitability & Returns
The company's Return on Equity (ROE) is 10.82%, while the Return on Capital Employed (ROCE) is 16.483%. The Earnings Per Share (EPS) is reported at Rs 12.44. The profit margin for the latest period is 13.93%.
Balance Sheet
Bliss GVS Pharma Ltd. has a book value of Rs 112.48. The debt-to-equity ratio is 0.05, indicating a low level of debt relative to equity.
Ownership & Pledges
As of March 31, 2026, promoter holding in Bliss GVS Pharma Ltd. was 35.3575%. FIIs held 10.4487% and DIIs held 5.0411% of the shares. Public shareholding was 49.1527%. There were no promoter shares pledged reported for the period.
Regulatory & Surveillance
Bliss GVS Pharma Ltd. is currently under LT-ASM (Additional Surveillance Measure) Stage 4. This indicates heightened monitoring by regulatory bodies due to specific criteria met by the scrip.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.